Specifically, Kymriah® (CD19-BB-z) became the first approved cell-based therapy for R/R B-ALL in patients under 25 years old, while Yescarta® (CD19-28-z) was approved for adult R/R B-NHL, based on the ELIANA,108,109 and and ZUMA-1110 trials, respectively. This evidence concerns the gene CD19 and non-Hodgkin lymphoma.